We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
+4.94%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.35B
AUM Growth
+$25.5M
Cap. Flow
+$32.7M
Cap. Flow %
2.42%
Top 10 Hldgs %
12.05%
Holding
2,121
New
584
Increased
441
Reduced
528
Closed
563

Top Sells

Rank Stock Value
1
LMND icon
Lemonade
LMND
+$4.64M
2
MGNI icon
Magnite
MGNI
+$3.66M
3
RELY icon
Remitly
RELY
+$3.66M
4
MNRO icon
Monro
MNRO
+$3.65M
5
VGR
Vector Group Ltd.
VGR
+$3.32M

Sector Composition

Rank Sector Weight
1 Technology 16.19%
2 Healthcare 13.13%
3 Financials 12.64%
4 Consumer Discretionary 12.16%
5 Industrials 9.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMSF icon
226
AMERISAFE
AMSF
$540M
$1.39M 0.1%
26,970
-16,621
-38% -$900K
AES icon
227
AES
AES
$10.5B
$1.39M 0.1%
107,769
+89,584
+493% +$1.34M
HRTG icon
228
Heritage Insurance Holdings
HRTG
$991M
$1.37M 0.1%
113,516
+13,461
+13% +$155K
MQ icon
229
Marqeta
MQ
$1.66B
$1.37M 0.1%
90,649
+32,049
+55% +$563K
OLPX
230
DELISTED
Olaplex Holdings
OLPX
$1.37M 0.1%
+789,996
New +$1.57M
ASML icon
231
ASML
ASML
$669B
$1.37M 0.1%
1,971
+217
+12% +$156K
OTTR icon
232
Otter Tail
OTTR
$3.94B
$1.36M 0.1%
18,415
-615
-3% -$48.2K
CRAI icon
233
CRA International
CRAI
$1.06B
$1.35M 0.1%
7,210
+4,616
+178% +$877K
ACAD icon
234
Acadia Pharmaceuticals
ACAD
$5.03B
$1.35M 0.1%
73,527
+6,431
+10% +$104K
CCL icon
235
Carnival Corporation Ltd
CCL
$39.7B
$1.34M 0.1%
53,724
+38,315
+249% +$897K
INTC icon
236
Intel
INTC
$513B
$1.34M 0.1%
+66,638
New +$1.5M
AUB icon
237
Atlantic Union Bankshares
AUB
$5.97B
$1.33M 0.1%
+35,174
New +$1.39M
SRTA
238
Strata Critical Medical Inc
SRTA
$512M
$1.33M 0.1%
313,520
-64,720
-17% -$246K
TIGR
239
UP Fintech Holding
TIGR
$860M
$1.33M 0.1%
205,683
-470,278
-70% -$3.23M
OSBC icon
240
Old Second Bancorp
OSBC
$1.29B
$1.32M 0.1%
74,500
-51,331
-41% -$892K
EOG icon
241
EOG Resources
EOG
$70.7B
$1.32M 0.1%
10,755
+651
+6% +$83.2K
FUTU icon
242
Futu Holdings
FUTU
$15.3B
$1.31M 0.1%
16,430
+9,193
+127% +$860K
TEL icon
243
TE Connectivity
TEL
$62.6B
$1.31M 0.1%
9,191
+7,545
+458% +$1.12M
CPRX
244
DELISTED
Catalyst Pharmaceutical
CPRX
$1.31M 0.1%
62,887
+31,450
+100% +$676K
PJT icon
245
PJT Partners
PJT
$4.38B
$1.31M 0.1%
+8,315
New +$1.27M
LMND icon
246
Lemonade
LMND
$4.1B
$1.31M 0.1%
35,737
-145,179
-80% -$4.64M
EXFY icon
247
Expensify
EXFY
$245M
$1.31M 0.1%
390,348
+296,906
+318% +$798K
PLOW icon
248
Douglas Dynamics
PLOW
$1.02B
$1.3M 0.1%
55,155
+36,887
+202% +$934K
HAL icon
249
Halliburton
HAL
$26.6B
$1.3M 0.1%
47,703
+7,445
+18% +$218K
TVTX icon
250
Travere Therapeutics
TVTX
$5.78B
$1.29M 0.1%
+74,356
New +$1.32M

Similar funds

GSA Capital Partners's Q4 2024 Portfolio in Review

As of Q4 2024, GSA Capital Partners held 2,121 positions worth $1.35B, up 1.9% from $1.32B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

GSA Capital Partners's Q4 2024 filing shows 584 new, 441 increased, 528 reduced and 563 closed positions. Its largest new stake was iShares Core S&P 500 ETF: 165,180 shares worth $97.2M. The largest sale was Lemonade, an estimated $4.64M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Healthcare and Financials.

  • GSA Capital Partners's largest Q4 2024 buy was iShares Core S&P 500 ETF: 165,180 shares worth $97.2M.
  • GSA Capital Partners added most to Frontline in Q4 2024, an estimated $5.7M increase.
  • GSA Capital Partners's biggest Q4 2024 reduction was Lemonade, cutting an estimated $4.64M.
  • GSA Capital Partners fully exited Monro in Q4 2024, selling an estimated $3.65M.
  • GSA Capital Partners's ten largest holdings make up 12% of its $1.35B portfolio in Q4 2024.
  • GSA Capital Partners opened 584 new positions and closed 563 in Q4 2024.
  • GSA Capital Partners's portfolio value rose 1.9% quarter-over-quarter to $1.35B.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.